Photodynamic Therapy Using Verteporfin for Treatment of Chronic Central Serous Chorioretinopathy … (NCT00211445) | Clinical Trial Compass
CompletedPhase 2
Photodynamic Therapy Using Verteporfin for Treatment of Chronic Central Serous Chorioretinopathy (CSC)
United States11 participantsStarted 2002-07
Plain-language summary
Central serous choroidal (CSC) retinopathy is a disease of the macula characterized by exudation of fluid under the retina localized to the posterior pole as well as loss of vision. The etiology is unknown, but according to the studies this condition is more common in young males and is associated with type A personality. Clinically, CSC is characterized by serous retinal detachment and area of leakage of in the subretinal space. The standard of care for acute CSC is observation for a period of up to 3 months. If there is no complete resolution of the retinal detachment by 3 months, there is an indication for focal laser photocoagulation therapy of the area of leakage. This treatment is usually effective in stopping leakage of fluid under the retina and causing resolution of detachment. However, laser photocoagulation therapy is not beneficial in the treatment of chronic CSC because there is not a single easily identifiable point of leakage but rather diffuse disease of RPE thus rendering laser treatment ineffective.The purpose of this medical research study is to evaluate Verteporfin therapy as an approach which may benefit patients with CSC, based on observations in exudative type of AMD patients treated with Photodynamic Therapy using Verteporfin.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Evidence of chronic central serous chorioretinopathy and clinical/angiographic findings typical of the disease of greater than 6 months duration.Chronic central serous chorioretinopathy could be defined on the basis of two factors: a) persistence of the detachment for more than 6 months and b) chronic recurrent acute detachments with widespread decompensation of the retinal pigment epithelium.
✓. VA 20/40 and 20/320 Study Eye on the ETDRS visual acuity chart.
✓. VA 20/800 or better Fellow Eye on the ETDRS visual acuity chart.
Exclusion criteria
✕. Patient with tears in retinal pigment epithelium.
✕. Patient with significantly compromised visual acuity in the study eye due to concomitant ocular conditions.
✕. Patients who have undergone intraocular surgery within last 2 months or capsulotomy within last month in study eye.
✕. Patient participating in any other investigational drug study.
✕. Inability to obtain photographs to document CNV (including difficulty with venous access).
What they're measuring
1
mean change in VA (ETDRS) from baseline to 24 months
Timeframe: 24 months
2
investigate the potential of photodynamic therapy using verteporpin in chronic central serous chorioretinopathy